<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36229409</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1398-9995</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Allergy</Title><ISOAbbreviation>Allergy</ISOAbbreviation></Journal><ArticleTitle>Effect of Haemophilus influenzae, Streptococcus pneumoniae and influenza vaccinations on infections, immune response and asthma control in preschool children with asthma.</ArticleTitle><Pagination><StartPage>1473</StartPage><EndPage>1488</EndPage><MedlinePgn>1473-1488</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/all.15551</ELocationID><Abstract><AbstractText Label="BACKGROUND">Haemophilus influenzae (H. influenzae), Streptococcus pneumoniae (pneumococcus) and influenza vaccines are administered in children to prevent infections caused by these pathogens. The benefits of vaccination for asthma control in children and the elicited immune response are not fully understood. This study aimed to investigate the impact of these vaccinations on respiratory infections, asthma symptoms, asthma severity and control status, pathogen colonization and in vitro immune responses to different stimulants mimicking infections in asthmatic children.</AbstractText><AbstractText Label="METHODS">Children aged 4-6&#x2009;years were recruited into the multicentre prospective PreDicta study conducted across five European countries. Information about vaccination history, infections, antibiotic use, inhaled corticosteroid (ICS) use and asthma symptoms in the last 12&#x2009;months were obtained from questionnaires of the study. Nasopharyngeal samples were collected at the first visit to assess bacterial and viral colonization, and venous blood for isolation of peripheral blood mononuclear cells (PBMCs). The PBMCs were stimulated with phytohemagglutinin, R848, Poly I:C and zymosan. The levels of 22 cytokines and chemokines were measured in cell culture supernatants using a luminometric multiplex assay.</AbstractText><AbstractText Label="RESULTS">One-hundred and forty asthmatic preschool children (5.3&#x2009;&#xb1;&#x2009;0.7&#x2009;years) and 53 healthy children (5.0&#x2009;&#xb1;&#x2009;0.8&#x2009;years) from the PreDicta cohort were included in the current study. Asthmatic children were associated with more frequent upper and lower respiratory infections, and more frequent and longer duration of antibiotic use compared with healthy children. In asthmatic children, sufficient H. influenzae vaccination was associated with a shorter duration of upper respiratory infection (URI) and overall use and average dose of ICS. The airway colonization was characterized by less pneumococcus and more rhinovirus. Pneumococcal vaccination was associated with a reduction in the use rate and average dose of ICS, improved asthma control, and less human enterovirus and more H. influenzae and rhinovirus (RV) airway colonization. Influenza vaccination in the last 12&#x2009;months was associated with a longer duration of URI, but with a decrease in the occurrence of lower respiratory infection (LRI) and the duration of gastrointestinal (GI) infection and antibiotic use. Asthmatic preschoolers vaccinated with H. influenzae, pneumococcus or influenza presented higher levels of Th1-, Th2-, Th17- and regulatory T cells (Treg)-related cytokines in unstimulated PBMCs. Under stimulation, PBMCs from asthmatic preschoolers with pneumococcal vaccination displayed a predominant anti-inflammatory immune response, whereas PBMCs from asthmatic children with sufficient H. influenzae or influenza vaccination were associated with both pro- and anti-inflammatory immune responses.</AbstractText><AbstractText Label="CONCLUSION">In asthmatic preschoolers, the standard childhood vaccinations to common respiratory pathogens have beneficial effects on asthma control and may modulate immune responses relevant to asthma pathogenesis.</AbstractText><CopyrightInformation>&#xa9; 2022 European Academy of Allergy and Clinical Immunology and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Ya-Dong</ForeName><Initials>YD</Initials><Identifier Source="ORCID">0000-0003-1251-7608</Identifier><AffiliationInfo><Affiliation>Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xepapadaki</LastName><ForeName>Paraskevi</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9204-1923</Identifier><AffiliationInfo><Affiliation>Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Yan-Wen</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Department of Allergology, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanic</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-2665-5772</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maurer</LastName><ForeName>Debbie J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-8543-1998</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Swiss Research Institute for Sports Medicine (SRISM), Davos, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachert</LastName><ForeName>Claus</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4742-1665</Identifier><AffiliationInfo><Affiliation>Upper Airway Research Laboratory, Ghent University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Upper Airway Research Laboratory, Ghent University Hospital, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finotto</LastName><ForeName>Susetta</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7623-7977</Identifier><AffiliationInfo><Affiliation>Department of Molecular Pneumology, Friedrich-Alexander-Universit&#xe4;t (FAU) Erlangen-N&#xfc;rnberg, Universit&#xe4;tsklinikum Erlangen, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chalubinski</LastName><ForeName>Maciej</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8311-9530</Identifier><AffiliationInfo><Affiliation>Department of Immunology and Allergy, Medical University of Lodz, Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lukkarinen</LastName><ForeName>Heikki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Oulu University Hospital, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passioti</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graser</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Pneumology, Friedrich-Alexander-Universit&#xe4;t (FAU) Erlangen-N&#xfc;rnberg, Universit&#xe4;tsklinikum Erlangen, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jartti</LastName><ForeName>Tuomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-2748-5362</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Oulu University Hospital, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PEDEGO Research Unit, University of Oulu, Oulu, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics and Adolescent Medicine, Oulu University Hospital, Oulu, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalski</LastName><ForeName>Marek</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8442-2774</Identifier><AffiliationInfo><Affiliation>Department of Immunology and Allergy, Medical University of Lodz, Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogulur</LastName><ForeName>Ismail</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-8282-7762</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Zi-Wei</ForeName><Initials>ZW</Initials><Identifier Source="ORCID">0000-0002-9276-6948</Identifier><AffiliationInfo><Affiliation>School of Public Health, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akdis</LastName><ForeName>M&#xfc;beccel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0554-9943</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadopoulos</LastName><ForeName>Nikolaos G</ForeName><Initials>NG</Initials><Identifier Source="ORCID">0000-0002-4448-3468</Identifier><AffiliationInfo><Affiliation>Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infection, Immunity &amp; Respiratory Medicine, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akdis</LastName><ForeName>Cezmi A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0001-8020-019X</Identifier><AffiliationInfo><Affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Allergy</MedlineTA><NlmUniqueID>7804028</NlmUniqueID><ISSNLinking>0105-4538</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013296" MajorTopicYN="N">Streptococcus pneumoniae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006193" MajorTopicYN="N">Haemophilus influenzae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001249" MajorTopicYN="Y">Asthma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Haemophiluse influenzae</Keyword><Keyword MajorTopicYN="N">asthma</Keyword><Keyword MajorTopicYN="N">immune response</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">pneumococcus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>13</Day><Hour>22</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36229409</ArticleId><ArticleId IdType="doi">10.1111/all.15551</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Jartti T, Liimatainen U, Xepapadaki P, et al. Clinical correlates of rhinovirus infection in preschool asthma. Allergy. 2021;76(1):247-254.</Citation></Reference><Reference><Citation>Murray CS, Jackson DJ, Teague WG. Prevention and outpatient treatment of asthma exacerbations in children. J Allergy Clin Immunol Pract. 2021;9(7):2567-2576.</Citation></Reference><Reference><Citation>Papadopoulos NG, Psarras S, Manoussakis E, Saxoni-Papageorgiou P. The role of respiratory viruses in the origin and exacerbations of asthma. Curr. Opin. Allergy Clin. Immunol. 2003;3(1):39-44.</Citation></Reference><Reference><Citation>Busse WW, Lemanske RF Jr, Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet. 2010;376(9743):826-834.</Citation></Reference><Reference><Citation>Akdis CA, Arkwright PD, Bruggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605.</Citation></Reference><Reference><Citation>Jackson DJ, Johnston SL. The role of viruses in acute exacerbations of asthma. J. Allergy Clin. Immunol. 2010;125(6):1178-1187. quiz 1188-1179.</Citation></Reference><Reference><Citation>Webley WC, Hahn DL. Infection-mediated asthma: etiology, mechanisms and treatment options, with focus on Chlamydia pneumoniae and macrolides. Respir. Res. 2017;18(1):98.</Citation></Reference><Reference><Citation>Sampath V, Rabinowitz G, Shah M, et al. Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. Allergy. 2021;76(6):1640-1660.</Citation></Reference><Reference><Citation>Martinez-Baz I, Navascues A, Casado I, et al. Effect of influenza vaccination in patients with asthma. CMAJ. 2021;193(29):E1120-E1128.</Citation></Reference><Reference><Citation>Guibas GV, Tsolia M, Christodoulou I, Stripeli F, Sakkou Z, Papadopoulos NG. Distinction between rhinovirus-induced acute asthma and asthma-augmented influenza infection. Clin Exp Allergy. 2018;48(5):536-543.</Citation></Reference><Reference><Citation>Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst. Rev. 2013;2013(2):CD000364.</Citation></Reference><Reference><Citation>Vasileiou E, Sheikh A, Butler C, et al. Effectiveness of influenza vaccines in asthma: a systematic review and meta-analysis. Clin. Infect. Dis. 2017;65(8):1388-1395.</Citation></Reference><Reference><Citation>Mehrabadi A, Dodds L, MacDonald NE, et al. Association of maternal influenza vaccination during pregnancy with early childhood health outcomes. JAMA. 2021;325(22):2285-2293.</Citation></Reference><Reference><Citation>Takeuchi H, Hasan SMT, Zaman K, et al. Impact of Haemophilus influenzae type b combination vaccination on asthma symptoms and pneumonia in 5-year-old children in rural Bangladesh: a longitudinal study and comparison with a previous cross-sectional study. Respir. Res. 2021;22(1):35.</Citation></Reference><Reference><Citation>Tang HHF, Lang A, Teo SM, et al. Developmental patterns in the nasopharyngeal microbiome during infancy are associated with asthma risk. J. Allergy Clin. Immunol. 2021;147(5):1683-1691.</Citation></Reference><Reference><Citation>Zaidi SR, Blakey JD. Why are people with asthma susceptible to pneumonia? A review of factors related to upper airway bacteria. Respirology. 2019;24(5):423-430.</Citation></Reference><Reference><Citation>Eisenlohr CP, Chartrand EM, Barzaga MR, Lanz MJ. Impact of pneumococcal vaccine response on asthma exacerbation frequency in young children. Immun Inflamm Dis. 2020;8(4):493-496.</Citation></Reference><Reference><Citation>Bernsen RM, Koes BW, de Jongste JC, van der Wouden JC. Haemophilus influenzae type b vaccination and reported atopic disorders in 8-12-year-old children. Pediatr. Pulmonol. 2006;41(5):463-469.</Citation></Reference><Reference><Citation>Laubereau B, Grote V, Holscher G, et al. Vaccination against Haemophilus influenzae type b and atopy in east German schoolchildren. Eur. J. Med. Res. 2002;7(9):387-392.</Citation></Reference><Reference><Citation>Xepapadaki P, Bachert C, Finotto S, et al. Contribution of repeated infections in asthma persistence from preschool to school age: Design and characteristics of the PreDicta cohort. Pediatr. Allergy Immunol. 2018;29(4):383-393.</Citation></Reference><Reference><Citation>Maurer DJ, Liu C, Xepapadaki P, et al. Physical activity in asthma control and its immune modulatory effect in asthmatic preschoolers. Allergy. 2021;77(4):1216-1230.</Citation></Reference><Reference><Citation>GINA. Global strategy for Asthma Management and Prevention. 2021. www.ginaasthma.org</Citation></Reference><Reference><Citation>Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732-738.</Citation></Reference><Reference><Citation>Krug J, Kiefer A, Koelle J, et al. TLR7/8 regulates type I and type III interferon signalling in rhinovirus 1b-induced allergic asthma. Eur. Respir. J. 2021;57(5):2001562.</Citation></Reference><Reference><Citation>Baldwin KT, Carbajal KS, Segal BM, Giger RJ. Neuroinflammation triggered by beta-glucan/dectin-1 signaling enables CNS axon regeneration. Proc. Natl. Acad. Sci. U. S. A. 2015;112(8):2581-2586.</Citation></Reference><Reference><Citation>Gern JE. Viral respiratory infection and the link to asthma. Pediatr. Infect. Dis. J. 2008;27(10 Suppl):S97-S103.</Citation></Reference><Reference><Citation>Busse WW. The precipitation of asthma by upper respiratory infections. Chest. 1985;87(1 Suppl):44&#x2009;S-48&#x2009;S.</Citation></Reference><Reference><Citation>Akdis CA. The epithelial barrier hypothesis proposes a comprehensive understanding of the origins of allergic and other chronic noncommunicable diseases. J. Allergy Clin. Immunol. 2022;149(1):41-44.</Citation></Reference><Reference><Citation>Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat. Rev. Immunol. 2021;21(11):739-751.</Citation></Reference><Reference><Citation>Angelina A, Martin-Fontecha M, Ruckert B, et al. The cannabinoid WIN55212-2 restores rhinovirus-induced epithelial barrier disruption. Allergy. 2021;76(6):1900-1902.</Citation></Reference><Reference><Citation>Jansen K, Wirz OF, van de Veen W, et al. Loss of regulatory capacity in Treg cells following rhinovirus infection. J. Allergy Clin. Immunol. 2021;148(4):1016-1029 e1016.</Citation></Reference><Reference><Citation>Wirz OF, Jansen K, Satitsuksanoa P, et al. Experimental rhinovirus infection induces an antiviral response in circulating B cells which is dysregulated in patients with asthma. Allergy. 2022;77(1):130-142.</Citation></Reference><Reference><Citation>Mazur NI, Martinon-Torres F, Baraldi E, et al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir. Med. 2015;3(11):888-900.</Citation></Reference><Reference><Citation>Coverstone AM, Wang L, Sumino K. Beyond respiratory syncytial virus and rhinovirus in the pathogenesis and exacerbation of asthma: the role of metapneumovirus, bocavirus and influenza virus. Immunol. Allergy Clin. N. Am. 2019;39(3):391-401.</Citation></Reference><Reference><Citation>Korppi M. Bacterial infections and pediatric asthma. Immunol. Allergy Clin. N. Am. 2010;30(4):565-574. vii.</Citation></Reference><Reference><Citation>Zhang J, Zhu Z, Zuo X, et al. The role of NTHi colonization and infection in the pathogenesis of neutrophilic asthma. Respir. Res. 2020;21(1):170.</Citation></Reference><Reference><Citation>Essilfie AT, Simpson JL, Dunkley ML, et al. Combined Haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma. Thorax. 2012;67(7):588-599.</Citation></Reference><Reference><Citation>Esposito S, Musio A, Principi N. Paediatric asthma and pneumococcal vaccination. Vaccine. 2013;31(44):5015-5019.</Citation></Reference><Reference><Citation>Pesek R, Lockey R. Vaccination of adults with asthma and COPD. Allergy. 2011;66(1):25-31.</Citation></Reference><Reference><Citation>Brealey JC, Chappell KJ, Galbraith S, et al. Streptococcus pneumoniae colonization of the nasopharynx is associated with increased severity during respiratory syncytial virus infection in young children. Respirology. 2018;23(2):220-227.</Citation></Reference><Reference><Citation>Preston JA, Thorburn AN, Starkey MR, et al. Streptococcus pneumoniae infection suppresses allergic airways disease by inducing regulatory T-cells. Eur. Respir. J. 2011;37(1):53-64.</Citation></Reference><Reference><Citation>Kim BG, Ghosh P, Ahn S, Rhee DK. Pneumococcal pep27 mutant immunization suppresses allergic asthma in mice. Biochem. Biophys. Res. Commun. 2019;514(1):210-216.</Citation></Reference><Reference><Citation>Sheen YH, Kizilbash S, Ryoo E, et al. Relationship between asthma status and antibody response pattern to 23-valent pneumococcal vaccination. J. Asthma. 2020;57(4):381-390.</Citation></Reference><Reference><Citation>Khetsuriani N, Kazerouni NN, Erdman DD, et al. Prevalence of viral respiratory tract infections in children with asthma. J. Allergy Clin. Immunol. 2007;119(2):314-321.</Citation></Reference><Reference><Citation>Schwarze J, Openshaw P, Jha A, et al. Influenza burden, prevention, and treatment in asthma-A scoping review by the EAACI Influenza in asthma task force. Allergy. 2018;73(6):1151-1181.</Citation></Reference><Reference><Citation>Ong BA, Forester J, Fallot A. Does influenza vaccination improve pediatric asthma outcomes? J. Asthma. 2009;46(5):477-480.</Citation></Reference><Reference><Citation>Essilfie AT, Simpson JL, Horvat JC, et al. Haemophilus influenzae infection drives IL-17-mediated neutrophilic allergic airways disease. PLoS Pathog. 2011;7(10):e1002244.</Citation></Reference><Reference><Citation>Castro-Rodriguez JA, Abarca K, Forno E. Asthma and the risk of invasive pneumococcal disease: a meta-analysis. Pediatrics. 2020;145(1):e20191200.</Citation></Reference><Reference><Citation>Osman HM, El Basha NR, Mansour AF, Hanna MOF. Serum IFNgamma-induced protein 10 (IP10/CXCL10): association with asthma exacerbations and severity in children. J. Asthma. 2022;59(11):2135-2142.</Citation></Reference><Reference><Citation>Ramakrishnan RK, Al Heialy S, Hamid Q. Role of IL-17 in asthma pathogenesis and its implications for the clinic. Expert Rev. Respir. Med. 2019;13(11):1057-1068.</Citation></Reference><Reference><Citation>Weng YH, Chen WY, Lin YL, Wang JY, Chang MS. Blocking IL-19 signaling ameliorates allergen-induced airway inflammation. Front. Immunol. 2019;10:968.</Citation></Reference><Reference><Citation>Xie M, Mustovich AT, Jiang Y, et al. IL-27 and type 2 immunity in asthmatic patients: association with severity, CXCL9, and signal transducer and activator of transcription signaling. J. Allergy Clin. Immunol. 2015;135(2):386-394.</Citation></Reference><Reference><Citation>Liu X, Li S, Jin J, et al. Preventative tracheal administration of interleukin-27 attenuates allergic asthma by improving the lung Th1 microenvironment. J. Cell. Physiol. 2019;234(5):6642-6653.</Citation></Reference><Reference><Citation>Borowczyk J, Shutova M, Brembilla NC, Boehncke WH. IL-25 (IL-17&#x2009;E) in epithelial immunology and pathophysiology. J. Allergy Clin. Immunol. 2021;148(1):40-52.</Citation></Reference><Reference><Citation>de Oliveira S, Reyes-Aldasoro CC, Candel S, Renshaw SA, Mulero V, Calado A. Cxcl8 (IL-8) mediates neutrophil recruitment and behavior in the zebrafish inflammatory response. J. Immunol. 2013;190(8):4349-4359.</Citation></Reference><Reference><Citation>Gao S, Wang J, Zhang Q, et al. Cytokine antibody array-based analysis of IL-37 treatment effects in asthma. Aging (Albany NY). 2021;13(17):21729-21742.</Citation></Reference><Reference><Citation>Jha A, Thwaites RS, Tunstall T, et al. Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis. J. Allergy Clin. Immunol. 2021;147(2):694-703 e612.</Citation></Reference><Reference><Citation>Gehlhar K, Bilitewski C, Reinitz-Rademacher K, Rohde G, Bufe A. Impaired virus-induced interferon-alpha2 release in adult asthmatic patients. Clin Exp Allergy. 2006;36(3):331-337.</Citation></Reference><Reference><Citation>Berry M, Brightling C, Pavord I, Wardlaw A. TNF-alpha in asthma. Curr. Opin. Pharmacol. 2007;7(3):279-282.</Citation></Reference><Reference><Citation>Teran LM. CCL chemokines and asthma. Immunol. Today. 2000;21(5):235-242.</Citation></Reference><Reference><Citation>Wang N, Brix S, Larsen JM, et al. Innate IL-23/Type 17 immune responses mediate the effect of the 17q21 locus on childhood asthma. Clin Exp Allergy. 2021;51(7):892-901.</Citation></Reference><Reference><Citation>Megremis S, Niespodziana K, Cabauatan C, et al. Rhinovirus Species-Specific Antibodies Differentially Reflect Clinical Outcomes in Health and Asthma. Am. J. Respir. Crit. Care Med. 2018;198(12):1490-1499.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>